Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

4.8%

2 terminated out of 42 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

14%

6 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed with results

Key Signals

5 with results83% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (3)
Early P 1 (2)
P 1 (11)
P 2 (7)
P 3 (5)
P 4 (1)

Trial Status

Recruiting14
Completed10
Unknown8
Not Yet Recruiting4
Active Not Recruiting3
Terminated2

Trial Success Rate

83.3%

Benchmark: 86.6%

Based on 10 completed trials

Clinical Trials (42)

Showing 20 of 20 trials
NCT07567846Phase 1RecruitingPrimary

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Phase 1RecruitingPrimary

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT07730580Phase 2Not Yet RecruitingPrimary

Study of XNW5004 Tablets in Advanced Prostate Cancer

NCT06369246Phase 1RecruitingPrimary

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

NCT07657806Phase 1Not Yet RecruitingPrimary

DEC003M in Prostate Cancer

NCT07650240Phase 2Not Yet Recruiting

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

NCT07198633Phase 1RecruitingPrimary

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

NCT07004582Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

NCT06555588Not ApplicableRecruiting

Engage Psychosocial Intervention for Cancer Symptoms

NCT07457164Phase 2Not Yet RecruitingPrimary

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

NCT06463457Phase 2Active Not Recruiting

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

NCT03938649Phase 2Active Not RecruitingPrimary

SRAM study_Postate Cancer

NCT06335914Not ApplicableRecruitingPrimary

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT07115446Phase 1RecruitingPrimary

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

NCT03511196Early Phase 1Active Not Recruiting

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT06062745Phase 1RecruitingPrimary

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT05590793Phase 3CompletedPrimary

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

NCT06769425Phase 1Recruiting

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT06984159Phase 3CompletedPrimary

The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

NCT03936218Phase 3CompletedPrimary

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Scroll to load more

Research Network

Activity Timeline